The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the ...

Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...

The MarketWatch News Department was not involved in the creation of this content. -- GEMORNA is world's first generative AI platform purpose-built for mRNA design and optimization, demonstrating state ...

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and creating new mRNA therapeutics, with 1.3 million euros ($1.47 million) in ...

Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology Sensible Biotechnologies, a biotechnology ...

The U.S. Department of Health and Human Services (HHS) has canceled almost $500 million in funding for mRNA vaccine projects, alleging worries about safety and efficacy. They are winding down nearly ...

At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising ...